552 related items for PubMed ID: 18622244
1. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nádházi Z, Petrella R, Sedefdjian A, Sévenier F, Shlyakhto EV, Pathak A.
J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
[Abstract] [Full Text] [Related]
2. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
Pathak A, Hanon O, Negre-Pages L, Sevenier F, OSCAR investigators.
Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
[Abstract] [Full Text] [Related]
3. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
Punzi HA, Punzi CF.
J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
[Abstract] [Full Text] [Related]
4. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Shlyakhto E.
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
[Abstract] [Full Text] [Related]
5. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
de la Sierra A, Muñoz A, Arcos E, López JS, Relats J, ETAPA-2 study investigators.
Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
[Abstract] [Full Text] [Related]
6. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I, Chilvers M, Reiz RJ.
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[Abstract] [Full Text] [Related]
7. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS, McKay DW, Reiz RJ.
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[Abstract] [Full Text] [Related]
8. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.
Labiós M, Martínez M, Gabriel F, Guiral V, Munoz A, Aznar J.
Am J Hypertens; 2004 Sep; 17(9):757-63. PubMed ID: 15363816
[Abstract] [Full Text] [Related]
9. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
Radaideh GA, Choueiry P, Ismail A, Eid E, Berrou JP, Sedefdjian A, Sévenier F, Pathak A.
Vasc Health Risk Manag; 2011 Sep; 7():491-5. PubMed ID: 21915165
[Abstract] [Full Text] [Related]
10. Association between eprosartan-based hypertension therapy and improvement in cognitive function score: long-term follow-up from the OSCAR observational study.
Hanon O, Lee YS, Pathak A, OSCAR Publication Group.
J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):366-73. PubMed ID: 23748626
[Abstract] [Full Text] [Related]
11. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of the ESTEPP Study.
Int J Clin Pract; 2005 Apr; 59(4):478-84. PubMed ID: 15853868
[Abstract] [Full Text] [Related]
12. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints.
Hanon O, Pequignot R, Seux ML, Lenoir H, Bune A, Rigaud AS, Forette F, Girerd X.
J Hypertens; 2006 Oct; 24(10):2101-7. PubMed ID: 16957572
[Abstract] [Full Text] [Related]
13. [Isolated systolic hypertension and cognitive function in the aged. Experience of the Syst-Eur study].
Seux ML, Thijs L, Forette F.
Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1169-72. PubMed ID: 9404430
[Abstract] [Full Text] [Related]
14. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O, Latour F, Seux ML, Lenoir H, Forette F, Rigaud AS, REAL.FR Group.
J Nutr Health Aging; 2005 Aug; 9(2):106-11. PubMed ID: 15791354
[Abstract] [Full Text] [Related]
15. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram CV, Rudmann MA.
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
[Abstract] [Full Text] [Related]
16. Effectiveness of eprosartan in diabetic hypertensive patients.
Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of ESTEPP Study.
Eur J Intern Med; 2008 Jan; 19(1):27-31. PubMed ID: 18206598
[Abstract] [Full Text] [Related]
17. [Stress-associated hypertension in the work place: results of the STARLET project].
Lüders S, Hammersen F, Kulschewski A, Frerichs A, Frieg R, Hahnheiser D, Reich G, Schnieders M, Schrandt G, Schrader J.
Dtsch Med Wochenschr; 2006 Nov 17; 131(46):2580-5. PubMed ID: 17096303
[Abstract] [Full Text] [Related]
18. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.
Sachse A, Verboom CN, Jäger B.
J Hum Hypertens; 2002 Mar 17; 16(3):169-76. PubMed ID: 11896506
[Abstract] [Full Text] [Related]
19. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB.
Am J Hypertens; 2006 Feb 17; 19(2):214-9. PubMed ID: 16448896
[Abstract] [Full Text] [Related]
20. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension.
Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K.
J Hypertens; 2008 Aug 17; 26(8):1636-41. PubMed ID: 18622243
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
